FDA Approves Nexavar For Patients With Inoperable Liver Cancer

The U.S. Food and Drug Administration announced that it has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.”In a randomized clinical trial, the group of patients with inoperable hepatocellular carcinoma who received Nexavar survived 2. [click link for full article]

More: continued here

Filed under: Cancer on November 20th, 2007